Older adults using Eli Lilly’s Zepbound (tirzepatide) for obesity face a significantly higher risk of death if they develop frailty-associated conditions like malnutrition, muscle wasting, or dehydration, according to a study by data analytics firm nference. While these conditions are rare overall, the risk of mortality for Zepbound users with malnutrition is roughly 25 times higher than for those without it.
Zepbound and Frailty Risks in Seniors
A study released on July 13 as a preprint by nference analyzed nearly 30,000 U.S. adults aged 65 and older treated with Zepbound. Researchers compared this group against nearly 19,000 patients using non-GLP-1 diabetes drugs and nearly 6,000 who underwent weight-loss surgery.
The data shows that frailty conditions are uncommon but dangerous. Only 0.16 per cent of all patients developed progressive declines in muscle mass and function, and 1.6 per cent experienced malnutrition. However, for those who did develop these issues, the outcomes were more severe for Zepbound users than for other groups.
Did you know? More than 41 per cent of U.S. adults aged 60 and older are obese, according to the Centers for Disease Control and Prevention (CDC). This creates a massive potential patient pool as Medicare expands access to GLP-1 therapies.
Comparing Mortality Risks Across Treatments
The nference study highlights a sharp contrast in how malnutrition, dehydration, and muscle wasting impact survival across different weight-loss and diabetes interventions. The risk of death was consistently highest for those on tirzepatide when these complications occurred.
| Condition | Zepbound (Tirzepatide) | Other Diabetes Drugs | Bariatric Surgery |
|---|---|---|---|
| Malnutrition | ~25-fold risk | ~7-fold risk | ~2-fold risk |
| Dehydration | ~6-fold risk | ~4-fold risk | ~2.5-fold risk |
| Muscle Wasting | ~12-fold risk | ~6-fold risk | ~2-fold risk |
These patterns also extended to ICU admissions and hospitalizations, with the highest odds found in the tirzepatide group, according to the report.
Clinical Guidance for Monitoring Older Patients
Venky Soundararajan, senior author of the nference report, stated that the findings do not prove tirzepatide caused these adverse outcomes. Instead, he suggests these signals may identify patients whose health is already deteriorating due to underlying illness or inadequate nutrition during rapid weight loss.
Soundararajan advises physicians to “intervene aggressively” the moment a signal of frailty appears by removing the patient from tirzepatide and increasing monitoring. The research indicates these conditions typically emerge after six months of treatment.
The Role of Muscle Mass in GLP-1 Weight Loss
The reduction of lean body mass is a primary concern for elderly patients. Preethi Srikanthan, a UCLA endocrinologist not involved in the study, noted that many older adults already start with low muscle reserves, making the loss of lean mass more impactful.
Srikanthan suggests that future research must determine if resistance exercise and protein supplementation can prevent this functional decline. She emphasizes that while clinicians should monitor for frailty, they should not avoid these treatments, as they remain effective for obesity and related heart failure.
Medicare Access and Market Trends
As of July 1, GLP-1 drugs for obesity became available to eligible Medicare Part D beneficiaries with a monthly copay of $50. Estimates suggest 3 to 4 million older adults may qualify for these therapies, increasing the urgency for standardized frailty assessment methods.
Frequently Asked Questions
Does Zepbound cause malnutrition in seniors?
The nference study does not conclude that the drug causes malnutrition, but it found that seniors who developed malnutrition while taking the drug had a significantly higher risk of death compared to those who did not.
When should doctors check for frailty in GLP-1 patients?
According to the nference researchers, frailty conditions typically emerged after six months of treatment, suggesting the need for ongoing, long-term monitoring.
Are these risks higher than weight-loss surgery?
Yes. The study found that the risk of death associated with malnutrition, dehydration, and muscle wasting was substantially higher for Zepbound users than for those who underwent bariatric surgery.
What are your thoughts on the balance between rapid weight loss and muscle preservation in older adults? Share your experience in the comments below or subscribe to our newsletter for the latest medical research updates.
Keep reading